• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Takeda to Expand U.S. Footprint

    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines

    WuXi STA Opens High-Potency API Plant

    Catalent Expands Primary Packaging Capabilities at its Shiga, Japan Facility

    Phastar Appoints Chris Schoonmaker as Chief Operations Officer
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Takeda to Expand U.S. Footprint

    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines

    WuXi STA Opens High-Potency API Plant

    Catalent Expands Primary Packaging Capabilities at its Shiga, Japan Facility

    Shimadzu Scientific Instruments Extends HQ Campus
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Takeda to Expand U.S. Footprint

    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines

    Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK

    EQT Private Equity Acquires SPT Labtech from Battery Ventures

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    IDT Biologika

    Quotient Sciences

    Vector Partners Limited

    Qosina

    Biosynth Carbosynth
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    IDT Biologika

    Quotient Sciences

    Vector Partners Limited

    Qosina

    Biosynth Carbosynth
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Akston Biosciences and Biolexis Enter COVID-19 Vaccine Partnership

    Collaborate to launch a room temperature stable second generation COVID-19 vaccine in more than 130 countries.

    03.18.22
    Akston Biosciences, a developer of new classes of biologic therapeutics, and Biolexis, a division of Stelis Biopharma, have entered into a licensing, manufacturing and commercialization agreement for Akston’s AKS-452, a protein subunit COVID-19 vaccine. Under the agreement, Biolexis gains the right to manufacture and commercialize AKS-452 (branded as AmbiVax-C) in India and over 130 countries in Asia, Latin America and Africa largely covering the low-and-middle-income countries (LMICs). Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships.

    AKS-452 or AmbiVax-C is a first-of-its-kind thermostable COVID-19 vaccine developed for all parts of the world. AmbiVax-C is a SARS-CoV-2 protein subunit vaccine designed to induce a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein. As the primary locus for infection, the RBD is highly conserved among mutated forms of the virus. The studies on AmbiVax-C have demonstrated robust antibody neutralization of variants, including Delta and Omicron, and the vaccine has been evaluated in multiple safety and efficacy studies in Netherlands and India across hundreds of subjects.

    AmbiVax-C does not include mRNA technology, viral vectors or a weakened SARS-CoV-2 virus and has been engineered to use established, low-cost antibody manufacturing techniques, such that a single production line could be capable of producing over one billion doses per year. AmbiVax-C is a two-shot vaccine injected over 28 days, with the first shot being supported by an adjuvant. The stability studies conducted on AmbiVax-C have demonstrated thermostability at room temperature for over six months at 25° Celsius (77° Fahrenheit) and maintains potency for one month at 37° Celsius (99° Fahrenheit). Being shelf-stable at these temperatures, AmbiVax-C has the potential to eliminate challenges in maintaining the cold chain, especially in low-and-middle-income countries where a significant population lacks dependable access to vaccines as a result of insufficient infrastructure to support the cold chain requirements of mRNA COVID-19 vaccines. AmbiVax-C would offer a flexible, reliable, and economically viable vaccine alternative in these regions, allowing the acceleration of immunization and longevity of immunity with the booster shots.

    “We are very excited to partner with Akston on AmbiVax-C, which is a first-of-its-kind COVID-19 vaccine developed for all parts of the world,” said Arun Kumar, founder, Strides Group. “While the vaccine has demonstrated good outcomes with its safety profile and over 90% seroconversion in clinical and bridging studies, its room temperature stability offers a unique value to the global population, making it more accessible across the World. As AmbiVax-C expects to receive EUA as a prime vaccine in H1 of 2022, we will leverage our group capabilities to manufacture, fill-finish, and commercialize AmbiVax-C across all the markets. We also remain on course to get the vaccine qualified as a booster to itself and other approved vaccines in different regions.”

    Todd Zion, president and CEO, Akston Biosciences, said, “We are very pleased to be working closely with Biolexis and Strides Group, which has the experience, know-how, and capability to produce our vaccine at scale. Just as importantly, the group can supply the vaccine to countries that need a practical and affordable way to protect their populations during this worldwide pandemic.”

    AmbiVax-C has completed Phase I and II studies at the University Medical Centre Groningen (UMCG) in the Netherlands. The recent Phase II trial data showed a greater than 90% seroconversion rate after two 45 μg doses (100%) or a single 90 μg dose (96%) in healthy adults at 56 days. It was well tolerated with a safety profile comparable to approved vaccines.

    An EUA determining Phase II/III clinical trial is currently underway in India for over 1,600 subjects. The bridging study of 100 subjects has already been completed with a favorable safety profile and greater than 90% seroconversion achieved on day 28 post two vaccines doses. Approval from the Subject Expert Committee (SEC) on vaccines of the Central Drugs Standard Control Organization (CDSCO), India, has been received to begin the dosing of the remaining 1,500 subjects. The studies are expected to conclude in April 2022 with a potential EUA within the H1 of 2022. Besides this, additional studies are also being pursued to qualify AmbiVax-C as a booster to itself or other approved vaccines.
    Related Searches
    • Biologics, Proteins, Vaccines
    • Clinical Trials

    Related Content

      Loading, Please Wait..
      Trending
      • Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
      • Almac Participates In Global Clinical Supply BlockChain Working Group
      • Regulatory Report: Analytical Procedure Development
      • Shimadzu Scientific Instruments Extends HQ Campus
      • Batavia Enters Commercial Manufacturing Business
      Breaking News
      • Takeda to Expand U.S. Footprint
      • Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines
      • WuXi STA Opens High-Potency API Plant
      • Catalent Expands Primary Packaging Capabilities at its Shiga, Japan Facility
      • Phastar Appoints Chris Schoonmaker as Chief Operations Officer
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Pharmavite Expands in Ohio with $200 Million Investment
      Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company
      Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products
      Coatings World

      Latest Breaking News From Coatings World

      Clariant’s Launches Dispersogen Flex 100
      Lincoln Tech Enters Partnership with AkzoNobel
      AkzoNobel Launches International Interzone 945GF
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      ENDRA Life Sciences Issued 27th Patent
      AI-Enabled SKOUT Device Improves Colorectal Cancer Screening
      Simon Johnson Appointed as Senior Business Development VP at MedAcuity
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Takeda to Expand U.S. Footprint
      Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines
      WuXi STA Opens High-Potency API Plant
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Latest Updates About Cosmoprof North America
      Meet the Clean Beauty Brand for Dogs
      Paco Rabanne Introduces Elle Fanning as Ambassador for New ‘Fame’ Fragrance
      Happi

      Latest Breaking News From Happi

      Two-Part Skincare Product Patented by Estée Lauder Companies
      American Cleaning Institute Pens Letter to Congress Encouraging Examination of Recyclability Improvements
      The Expert Panel for Fragrance Safety Celebrates 55 Years
      Ink World

      Latest Breaking News From Ink World

      INX Launches INXFlex Contour for Shrink Sleeve Market
      Xerox Announces Unexpected Passing of Vice Chairman and CEO John Visentin
      MNYPIA Golf Outing Set to Tee Off on Aug. 17
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Meyers purchased by third generation of Dillon family
      Epson now shipping ColorWorks C4000 inkjet label printer
      Nobelus launches new films for prime labels
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      What You’re Reading on Nonwovens-Industry.com
      Daio, Livedo Partner to Recycle Diapers
      Suominen Launches Hydraspun Reserve
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      3D Systems and EMS-GRILTECH Enter Strategic Partnership
      AIP Researchers Develop Microfluidic-Based Soft Robotic Prosthetic
      David Sharp Named Global Marketing VP at Catalyst OrthoScience
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Impinj Launches E910 RFID Reader Chip for Next Generation Enterprise IoT
      onsemi Receives Recognition for Sustainability for Third Straight Year
      Xerox Announces the Unexpected Passing of Vice Chairman and CEO John Visentin

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login